about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Wad­ing deep­er in­to tar­get dis­cov­ery and val­i­da­tion, Im­mu­nai bags $60M to beef up both AI al­go­rithms and lab bench­es

5 years ago
Financing
AI

All in on ide-cel, Bris­tol My­ers Squibb writes off $470M as sec­ond BC­MA CAR-T is eject­ed from the pipeline

5 years ago
R&D

Af­ter purg­ing its own can­di­dates, Mer­ck says it's ready to as­sist in Covid-19 vac­cine pro­duc­tion

5 years ago
Coronavirus

As US da­ta for Covid-19 vac­cine loom, As­traZeneca cleans house and scraps sev­er­al asth­ma, can­cer drugs from pipeline

5 years ago
R&D

With a ros­ter of gene ther­a­py vets, For­bion makes a bet on 'rel­a­tive­ly emp­ty space' of vec­tor­ized an­ti­bod­ies

5 years ago
Startups
Cell/Gene Tx

Eli Lil­ly racks up EUA for an­ti­body cock­tail — but the big­ger chal­lenge is still ahead

5 years ago
FDA+
Coronavirus

With Lib­tay­o's sec­ond ap­proval, Re­gen­eron digs deep­er in­to PD-1 der­ma­to-on­col­o­gy niche

5 years ago
FDA+

J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter ...

5 years ago
News Briefing

Months af­ter shock­ing house ar­rest, Leg­end co-founder Frank Zhang is out on bail — though the CAR-T play­er has ...

5 years ago
People
China

Learn­ing from oth­er­s' mis­takes, low-pro­file mi­croR­NA biotech looks to prove it­self in the clin­ic

5 years ago
R&D

A syn­thet­ic lethal­i­ty play­er emerges in Chi­na, armed with lessons on un­drug­gable onco­gene from No­bel lau­re­ate's lab

5 years ago
Financing
Startups

Re­gen­eron stum­bles in PhI Lib­tayo com­bo study as safe­ty con­cerns force sus­pen­sion

5 years ago
R&D

FDA slaps clin­i­cal hold on an­tibi­otics tri­al af­ter deaths in mon­key tri­al spurred con­cerns

5 years ago
FDA+

As­traZeneca's Imfinzi fails main OS end­point in PhI­II for head and neck can­cer — and adding treme­li­mum­ab didn’t ...

5 years ago
R&D

Roche chops TNBC pro­grams fol­low­ing PhI­II flops, fur­ther dim­ming the spot­light on Ar­ray drug

5 years ago
R&D

Weighed down by safe­ty con­cerns of JAK port­fo­lio, Pfiz­er hatch­es a deal to go a dif­fer­ent di­rec­tion in rheuma­toid ...

5 years ago
Deals

Mer­ck KGaA goes toe to toe with No­var­tis as FDA green-lights MET in­hibitor

5 years ago
Pharma
FDA+

Biotech scan­dal drags on as the feds on­ly score par­tial vic­to­ry against ex­ecs charged with cook­ing the books

5 years ago
People

Ea­ger to re­deem its Covid-19 vac­cine, As­traZeneca touts 82.4% ef­fi­ca­cy for 12-week dos­ing sched­ule — but will the ...

5 years ago
R&D
Coronavirus

Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

5 years ago
Deals
Coronavirus

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

5 years ago
News Briefing

FDA lifts clin­i­cal hold on Mus­tang Bio's lentivi­ral gene ther­a­py, paving the way for quick jump in­to piv­otal tri­al

5 years ago
Cell/Gene Tx
FDA+

Ver­tex is poised for a shop­ping spree. But it’s still un­clear just what might go in­to their bas­ket — and at least ...

5 years ago
Deals

Ar­cutis show­cas­es pos­i­tive PhI­II da­ta show­ing its top­i­cal cream scratched the sweet spot Ote­zla or steroids could­n't

5 years ago
R&D
First page Previous page 56575859606162 Next page Last page
A service from the Financial Times